Lessons from China and the United States on the use of RWE in regulatory submissions
As the world raced to develop vaccines and therapeutics to combat the global coronavirus pandemic in 2020, the use of real-world evidence (RWE) accelerated because it offers an opportunity to support faster, more cost-effective drug and vaccine development. It also benefits clinical trial patients with rare and life-threatening diseases. For example, RWE-based external control arms could ensure patients receive an active treatment in a clinical trial, rather than be allocated to a placebo control regimen. The United States and China are at the forefront of exploring how RWE could support regulatory decisionmaking.
At Parexel, we’ve learned how companies can be more effective at collecting real-world data (RWD) and generating RWE. In this article, we share our most valuable lessons.
Related Insights
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Video
The science and practice of ethnobridging
May 17, 2023
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Related Insights
Blog
Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market
Nov 13, 2023
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Video
The science and practice of ethnobridging
May 17, 2023
Blog
A hybrid model supports globally diverse site participation for a retrospective cancer study
Jul 24, 2023
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Playbook
Streamlining success: How integrated evidence planning transforms asset development
Feb 27, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Article
Six top tips to prepare for the new EU Clinical Trial Regulation
Apr 13, 2021
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022